

### **Market Data**

BullFrog Al	
Nasdaq: <b>BFRG</b>	

Price	\$2.68
52-wk Range	\$1.43-8.35
Market Cap	\$21.2M
Shares Out.	7.9M
Float	5.2M
Revenue (ttm) <sup>1</sup>	\$70k
Cash (mrq) <sup>1</sup>	\$7.0M
Avg. Vol (90-day)	167,323

Price & share data as of July 17, 2024 ' As of March 31, 2024

## bullfrogai.com



Using AI to Precisely Identify the Molecular Drivers of Disease to Enable the Discovery of Novel Drug Targets and Accelerate the Development of Effective Therapies

## **Company Overview**

BullFrog AI is revolutionizing drug development through the use of scientific machine learning and causal AI. A pioneering technology-enabled drug discovery company, BullFrog AI utilizes its ensemble of AI technologies, including its proprietary bfLEAP™ graph-based analytics platform, to precisely identify causal molecular drivers of disease, enabling the discovery of novel drug targets. BullFrog AI's advanced analytics platform transforms the drug discovery process by leveraging multimodal data sets to identify causal drivers of disease and defining the position of related proteins within biological networks. This enables a deeper understanding of the disease process and of the therapeutic potential of drug target candidates, thereby minimizing failure rates for new therapeutics. BullFrog AI's mission is to transform drug discovery and development, ultimately improving the lives of countless patients by delivering the therapies they need.

### **Investment Highlights**

#### **Exclusive Licensing Deals with Leading Research Institutions**

- Preclinical phase siRNA obesity drug candidate; obesity market size expected to grow to \$77B by 2030
- Phase 2 ready Mebendazole formulation along with preclinical stage novel
  Mebendazole prodrug for glioblastoma and additional oncology indications; glioblastoma market size was \$2.1 billion in 2020, expected to grow at 8.8% CAGR between 2021-2028
- Exclusive partnership with the Lieber Institute provides exclusive access to brain data and a strong competitive edge in targeting companies focused on the development of drugs targeting central nervous system disorders; CNS therapeutics market ~\$117 billion in 2022 and expected to surpass \$140 billion in 2026
  - Multiple novel drug targets already identified and early results demonstrated biological stratification of brain expression data, offering potentially unprecedented insights into psychiatric conditions
- Discovery phase oncolytic virus program with J Craig Venter Institute

#### Proprietary bfLEAP™ AI Platform

- Ensemble of proprietary AI/ML technologies and processes
- Unsupervised AI/ML platform has ability to make predictions with incomplete data and reveal meaningful insights without pre-existing hypotheses
- Proprietary clustering algorithms find non-linear, multi-variate relationships in large, highly complex data sets
- Components of bfLEAP<sup>™</sup>'s algorithm suite selected as finalist for the R&D 100 Awards
- Lieber Institute for Brain Development Collaboration
- Partnership has allowed BullFrog AI to analyze comprehensive genomic and phenotypic data from post-mortem human brains using bfLEAP<sup>™</sup> and causal AI, leading to the identification of novel molecular subtypes and potential therapeutic targets for neuropsychiatric disorders
- BullFrog AI has used this information to identify key genetic loci and gene expression markers that could guide the development of more effective drugs for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder.

#### **Accomplished Leadership Team**

- Vin Singh, Founder, Chairman & CEO; extensive knowledge in electrical and biomedical engineering. Former CEO of Next Healthcare Inc and co-founder of MaxCyte (Nasdaq: MXCT)
- Dr. Tom Chittenden, CSO; distinguished career at intersection of AI, machine learning, drug discovery, and biostatistics; previously President/CSO at BioAI Health, President/CTO at HiberCell, and President/CTO and Founding Director of the Genuity Artificial Intelligence Research Institute at Genuity Science

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or triang losses and damages that may arises out of the use of information provided to any person or entity for the quality, accuracy, completeness of this information, special star, advisors, and partners will not be liable to any gains or losses that result from the opinions expressed in the opinions expressed in the average start that any result from any inaccuracy or incompleteness of this information provided, or information provided to any person or entity for the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentiations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investor. For more information on sock market investing, wisit the Securities and Exchange Com





### Pipeline with Worldwide Exclusive Rights

Demonstrated success advancing in-licensed assets

DISCOVERY	PRECLINICAL	PHASE I	PHASE II	PHASE III
BF-222 (SMALL MOLECUL	E): GLIOBLASTOMA			~
	GLIOBLASTOMA			
BF-223 (SMALL MOLECUL	E): GLIOBLASTOMA			~
CLIOBL	ASTOMA			
BF-114: DBESITY AND CHR	ONIC LIVER DISEASES			~
LIVER CANCER (HCC)				
MORBID OBESITY				
NASH				
NAFLD				
MODIFIED HSV-1: COLORED	TAL CANCER			~
COLORECTAL CANCER				

# Value Proposition

BullFrog AI is revolutionizing the biopharma industry with its innovative bfLEAP<sup>™</sup> platform, an AI-driven solution designed to enhance drug development success rates while reducing development time and costs. Recognized with awards such as Johns Hopkins APL Technology of the Year (2018) and R&D100 Award Finalist (2023), bfLEAP<sup>™</sup> leverages over 250 analytical functions to provide unparalleled accuracy and efficiency in drug discovery and drug target identification. By incorporating causal AI, BullFrog AI precisely identifies the molecular drivers of diseases, enabling the discovery of novel drug targets and accelerating the development of effective therapeutics.


Exclusive partnerships with prestigious institutions like the Lieber Institute for Brain Development (LIBD) grant BullFrog AI access to disease-focused datasets that can be leveraged for drug target discovery. The LIBD collaboration has already identified novel drug targets for neuropsychiatric disorders, and early results demonstrate previously unknown biological stratification of brain expression data, offering potentially unprecedented insights into psychiatric conditions. These insights are poised to drive innovation in CNS therapeutics, a market projected to reach \$200 billion annually by 2028.

BullFrog Al's lean operational model ensures maximum resource allocation towards growth and innovation, enabling agile market responses. The company's technology directly addresses the biopharma sector's critical challenge: the low 12% success rate of drugs transitioning from clinical trials to market. With annual R&D spending expected to hit \$204 billion in 2024, BullFrog Al's solutions are addressing a massive market opportunity.

Positioned at the forefront of Al-driven drug discovery and drug target identification, BullFrog Al offers a compelling investment opportunity with its powerful technology, strategic partnerships, and efficient operations.

### Improving Odds of Success with AI-enabled Discovery and Development

- Drug Target Identification
- Patient Stratification for Trial Design and Optimization
- Drug Repositioning
- Real-World Data Analytics



### **Data Inputs Include:**

- BullFrog-exclusive data
- Client-provided data
- Third-party data

Graph /ML Analytics / Explainable Al

Scalable Analytics / Data Agnostic

Multimodal / Incomplete Data

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or triangle losses and damages that may ares out of the use of information provided to any person or entity for the quality, accuracy, completeness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investion. For more information on stock market investing a structure or intervestor avarenees services and programs are designed to help small-cap companies, lnce. Bufformation on stock market investing and three sections companies, lnce. Bufformation on stock market investing a structure at the sectio